AFT Pharmaceuticals Wins Court of Appeal Case Over Pascomer Profits

MT Newswires Live

Mar 09

AFT Pharmaceuticals (ASX:AFP, NZE:AFT) said that the court of appeal has dismissed PBL Solutions' bid to claim a share of profits from the company's use of its topical skin medicine Pascomer for treating port wine stains (PWS), according to a Monday filing with the Australian and New Zealand bourses.

The ruling allows the company to retain full profits from Pascomer's use in treating non-orphan conditions like PWS, per the filing.

PBL, holding a 35% stake in AFT Orphan Pharmaceuticals, will receive 35% of any profits from Pascomer orphan drug applications, the filing said.

PBL and the company will share the appeal costs, and the company does not expect the judgment to materially affect its fiscal year 2026 earnings guidance, the filing added.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2618692420"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2618692420\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2618692420?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-09 08:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618692420","market":"nz","top_or_hot":-1,"title":"AFT Pharmaceuticals Wins Court of Appeal Case Over Pascomer Profits","media":"MT Newswires Live","content":"<html><body><p> AFT Pharmaceuticals (ASX:AFP, NZE:AFT) said that the court of appeal has dismissed PBL Solutions' bid to claim a share of profits from the company's use of its topical skin medicine Pascomer for treating port wine stains (PWS), according to a Monday filing with the Australian and New Zealand bourses.</p><p>The ruling allows the company to retain full profits from Pascomer's use in treating non-orphan conditions like PWS, per the filing.</p><p>PBL, holding a 35% stake in AFT Orphan Pharmaceuticals, will receive 35% of any profits from Pascomer orphan drug applications, the filing said.</p><p>PBL and the company will share the appeal costs, and the company does not expect the judgment to materially affect its fiscal year 2026 earnings guidance, the filing added.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AFT Pharmaceuticals Wins Court of Appeal Case Over Pascomer Profits</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAFT Pharmaceuticals Wins Court of Appeal Case Over Pascomer Profits\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-03-09 08:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> AFT Pharmaceuticals (ASX:AFP, NZE:AFT) said that the court of appeal has dismissed PBL Solutions' bid to claim a share of profits from the company's use of its topical skin medicine Pascomer for treating port wine stains (PWS), according to a Monday filing with the Australian and New Zealand bourses.</p><p>The ruling allows the company to retain full profits from Pascomer's use in treating non-orphan conditions like PWS, per the filing.</p><p>PBL, holding a 35% stake in AFT Orphan Pharmaceuticals, will receive 35% of any profits from Pascomer orphan drug applications, the filing said.</p><p>PBL and the company will share the appeal costs, and the company does not expect the judgment to materially affect its fiscal year 2026 earnings guidance, the filing added.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7096","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2618692420","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2618692420","pubTimestamp":1773015366,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"AFT Pharmaceuticals  said that the court of appeal has dismissed PBL Solutions' bid to claim a share of profits from the company's use of its topical skin medicine Pascomer for treating port wine stains , according to a Monday filing with the Australian and New Zealand bourses.The ruling allows the company to retain full profits from Pascomer's use in treating non-orphan conditions like PWS, per the filing.PBL, holding a 35% stake in AFT Orphan Pharmaceuticals, will receive 35% of any profits from Pascomer orphan drug applications, the filing said.PBL and the company will share the appeal costs, and the company does not expect the judgment to materially affect its fiscal year 2026 earnings guidance, the filing added.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7096":"制药","PWS":"Pacer WealthShield ETF","AFP.AU":"AFT PHARMACEUTICALS LTD","AFT":"Apollo Senior Floating Rate Fund"},"translate_title":"AFT Pharmaceuticals赢得上诉法院关于Pascomer利润的案件","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PWS":1,"AFP.AU":1,"AFT":1.5},"content_text":"AFT Pharmaceuticals (ASX:AFP, NZE:AFT) said that the court of appeal has dismissed PBL Solutions' bid to claim a share of profits from the company's use of its topical skin medicine Pascomer for treating port wine stains (PWS), according to a Monday filing with the Australian and New Zealand bourses.The ruling allows the company to retain full profits from Pascomer's use in treating non-orphan conditions like PWS, per the filing.PBL, holding a 35% stake in AFT Orphan Pharmaceuticals, will receive 35% of any profits from Pascomer orphan drug applications, the filing said.PBL and the company will share the appeal costs, and the company does not expect the judgment to materially affect its fiscal year 2026 earnings guidance, the filing added.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}